HC Wainwright Upgrades Upstream Bio (NASDAQ:UPB) to “Strong-Buy”

Upstream Bio (NASDAQ:UPB) was upgraded by research analysts at HC Wainwright to a “strong-buy” rating in a report issued on Wednesday,Zacks.com reports.

Several other brokerages also recently commented on UPB. Weiss Ratings downgraded Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Wall Street Zen downgraded Upstream Bio from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Evercore lowered Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price objective for the company. in a research note on Friday, March 27th. Finally, Mizuho lowered their price objective on Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $38.20.

Upstream Bio Stock Performance

Shares of NASDAQ:UPB opened at $7.63 on Wednesday. The company has a market cap of $415.22 million, a P/E ratio of -2.62 and a beta of 1.10. Upstream Bio has a one year low of $7.18 and a one year high of $33.68. The business’s 50-day simple moving average is $9.12 and its 200 day simple moving average is $17.70.

Upstream Bio (NASDAQ:UPB) last announced its earnings results on Wednesday, May 13th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.02). The company had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $1.03 million. Upstream Bio had a negative net margin of 4,718.96% and a negative return on equity of 43.82%. Analysts predict that Upstream Bio will post -2.99 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in UPB. Integral Health Asset Management LLC acquired a new position in Upstream Bio in the 3rd quarter worth about $10,816,000. Jennison Associates LLC acquired a new position in Upstream Bio in the 4th quarter worth about $7,842,000. Pictet Asset Management Holding SA acquired a new position in Upstream Bio in the 4th quarter worth about $20,991,000. UBS Group AG increased its position in Upstream Bio by 563.4% in the 4th quarter. UBS Group AG now owns 1,806,243 shares of the company’s stock worth $49,039,000 after purchasing an additional 1,533,972 shares during the last quarter. Finally, Rafferty Asset Management LLC acquired a new position in Upstream Bio in the 3rd quarter worth about $649,000.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.